Synaptogenix Inc (SNPX)

[SF Wolf]

MARCH 27TH could be a significant day for Neurotrope:

Dr. Daniel Alkon, President and Chief Science Officer of Neurotrope Bioscience, Inc. will be the Confirmed Keynote Speaker at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum. Dr. Alkon will speak at 1:30 PM at this one day conference.


The “ 2nd Annual Neuroscience BioPartnering & Investment Forum (is) to take place on the 27th of March at the New York Academy of Sciences. Event will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. We anticipate over 200 delegates and more than 20 presentations by listed and private biotechnology companies seeking licensing & investment opportunities.”

“Therapeutic Panels will include:
Advances in Alzheimer’s Disease
Parkinson’s Disease & Other Movement Disorders
Rare & Orphan Diseases
Neuropsychiatry & Pain Management”

“Confirmed Keynote include:
Dr. Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.”
http://www.sachsforum.com/2nbpi-about.html

Confirmed Attending Companies Include: (Neurotrope, Astra Zeneca, Johnson & Johnson, Lilly, Merck, Roche, etc.) http://www.sachsforum.com/2nbpi-attendees.html

Confirmed Financial, Advisory and Investors Include: (Aegis Capital, Lexington Capital, Michael J. Fox Foundation, Piper Jaffray, The Alzheimer’s Drug Discovery Foundation, etc.) http://www.sachsforum.com/2nbpi-investors.html